CJC-1295
Growth Hormone Peptides
Also known as: CJC-1295 DAC, Modified GRF(1-29)
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life due to Drug Affinity Complex (DAC) technology.
- Dose in studies
- 1-2 mg per week (with DAC) or 100 mcg 2-3x daily (no DAC)
- Frequency
- Weekly (with DAC) or 2-3x daily (no DAC)
- Cycle length
- 8-16 weeks on, 4-8 weeks off
- Half-life
- ~6-8 days (with DAC)
- Research level
- 2/5 – Limited research
Frequently asked questions about CJC-1295
What is CJC-1295?
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life due to Drug Affinity Complex (DAC) technology.
What is the half-life of CJC-1295?
The half-life of CJC-1295 is ~6-8 days (with DAC).
What dosage of CJC-1295 has been studied?
Described in research: 1-2 mg per week (with DAC) or 100 mcg 2-3x daily (no DAC), frequency: Weekly (with DAC) or 2-3x daily (no DAC). This is not a medical recommendation.
How long is a CJC-1295 cycle?
Typical cycle length in studies: 8-16 weeks on, 4-8 weeks off.
What are the side effects of CJC-1295?
Injection site reactions: Localized redness, swelling, or hardness at the injection site. Rotate sites regularly. Typically mild and resolves within hours. · Water retention: Moderate fluid retention, especially during the first 4 weeks. Reducing sodium intake and staying hydrated helps manage this. · Increased appetite: Hunger increase due to GHRH activation. Less pronounced than GHRP-type…
How well researched is CJC-1295?
Limited research (2/5). Few, small or uncontrolled human data; mostly animal studies.